Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 17, 2025Frontiers in ImmunologyOpen Access

Long-term follow-up of patients with relapsed/refractory multiple myeloma after BCMA CAR-T-cell therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

YHYuanyuan HaoZWZhen WangLZLei Zhang

Discussion

Loading...

Member takes

Overview

Single-center experience highlights long-term efficacy and safety in patients with relapsed/refractory multiple myeloma, suggesting favorable outcomes.

Key Points

  • Overall response rate of 72.7% observed in patients with relapsed/refractory multiple myeloma who received treatment.
  • Median progression-free survival and overall survival for responders both reached 35 months, indicating durable responses.
  • Most patients experienced moderate cytokine release syndrome, with some cases being more severe, showcasing treatment-related effects.
  • Long-term follow-up revealed that 50% of responders remained alive and relapse-free at the data cutoff.

Cite This Study

Hao et al. (2025) studied this question.

synapsesocial.com/papers/68d43285713b0b5dfea71a9dhttps://doi.org/10.3389/fimmu.2025.1650568
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1BCMA-CART therapy in 29 cases of relapsed or refractory multiple myeloma:a retrospective study2025
  2. 2Correlation between the expression of soluble BCMA and short-term/long-term curative effect and survival outcomes of anti-BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma2025
  3. 3Anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma with extramedullary disease: Comparative outcomes and evolving strategies2025
  4. 4BCMA-targeted CAR T-cell therapy in refractory autoimmune diseases: Initial Results from a Phase 1 clinical trial2025 · 1 citations
  5. 5BCMA CAR T-cell therapy in newly diagnosed primary plasma cell leukemia ineligible for transplantation: An open label, single-arm, phase 2 study (CAREMM-002)2025 · 2 citations